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Abstract
Background—Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 
80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do 
initially respond then develop resistance to treatment. Agonists that target the shared interleukin-2 
(IL-2) and IL-15Rβγ pathway have induced complete and durable responses in some cancers, but 
no studies have been done to assess the safety or efficacy of these agonists in combination with 
anti-PD-1 immunotherapy. We aimed to define the safety, tolerability, and activity of this drug 
combination in patients with NSCLC.
Methods—In this non-randomised, open-label, phase 1b trial, we enrolled patients (aged ≥18 
years) with previously treated histologically or cytologically confirmed stage IIIB or IV NSCLC 
from three academic hospitals in the USA. Key eligibility criteria included measurable disease, 
eligibility to receive anti-PD-1 immunotherapy, and an Eastern Cooperative Oncology Group 
performance status of 0 or 1. Patients received the anti-PD-1 monoclonal antibody nivolumab 
intravenously at 3 mg/kg (then 240 mg when US Food and Drug Administration [FDA]-approved 
dosing changed) every 14 days (either as new treatment or continued treatment at the time of 
disease progression) and the IL-15 superagonist ALT-803 subcutaneously once per week on weeks 
1–5 of four 6-week cycles for 6 months. ALT-803 was administered at one of four escalating dose 
concentrations: 6, 10, 15, or 20 μg/kg. The primary endpoint was to define safety and tolerability 
and to establish a recommended phase 2 dose of ALT-803 in combination with nivolumab. 
Analyses were per-protocol and included any patients who received at least one dose of study 
treatment. This trial is registered with ClinicalTrials.gov, number NCT02523469; phase 2 
enrolment of patients is ongoing.
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Findings—Between Jan 18, 2016, and June 28, 2017, 23 patients were enrolled and 21 were 
treated at four dose levels of ALT-803 in combination with nivolumab. Two patients did not 
receive treatment because of the development of inter-current illness during enrolment, one patient 
due to leucopenia and one patient due to pulmonary dysfunction. No dose-limiting toxicities were 
recorded and the maximum tolerated dose was not reached. The most common adverse events 
were injection-site reactions (in 19 [90%] of 21 patients) and flu-like symptoms (15 [71%]). The 
most common grade 3 adverse events, occurring in two patients each, were lymphocytopenia and 
fatigue. A grade 3 myocardial infarction occurred in one patient. No grade 4 or 5 adverse events 
were recorded. The recommended phase 2 dose of ALT-803 is 20 μg/kg given once per week 
subcutaneously in combination with 240 mg intravenous nivolumab every 2 weeks.
Interpretation—ALT-803 in combination with nivolumab can be safely administered in an 
outpatient setting. The promising clinical activity observed with the addition of ALT-803 to the 
regimen of patients with PD-1 monoclonal antibody relapsed and refractory disease shows 
evidence of anti-tumour activity for a new class of agents in NSCLC.
Introduction
Immunotherapy with monoclonal antibodies targeting PD-1 and PD-L1 has transformed the 
treatment of non-small-cell lung cancer (NSCLC) since initial regulatory approval in 
2015.1–4 These treatments exert their effect by disrupting the interaction between the 
inhibitory ligand PD-L1 and its receptor PD-1, leading to functional recovery of anti-tumour 
lymphocytes. Although second-line treatment with anti-PD-1 immunotherapy can induce 
durable clinical responses, roughly 80% of unselected NSCLC patients will not respond to 
treatment, and nearly all of those who do initially respond will eventually develop resistant 
disease.1,2 Recent studies also suggest that targeting the PD-1 pathway can benefit patients 
in the first line, either before or in combination with platinum-based chemotherapy.3,4 For 
patients with disease resistant to PD-1 blockade, the use of combination therapies offers the 
potential to target additional pathways to improve the proportion of patients achieving a 
response. In metastatic melanoma, the addition of the anti-CTLA-4 monoclonal antibody 
ipilimumab to anti-PD-1 monoclonal antibody treatment with nivolumab improves the 
efficacy of single-agent nivolumab therapy, although many patients report grade 3 and 4 
adverse events.5 This combination of ipilimumab and nivolumab received the first ever US 
Food and Drug Administration (FDA) approval for the combination of two immunotherapy 
drugs in 2015, and is being investigated in NSCLC (NCT02477826). The assessment of 
other PD-1-targeted treatments in combination has also shown promise, including the use of 
use of anti-CD137 (4–1BB) monoclonal antibodies and pegylated IL-10.6,7
In contrast to previously used combinatorial agents, IL-2 and IL-15-based treatments target 
the shared IL-2Rβγ pathway in lymphocytes. Approved for use by the FDA nearly three 
decades ago, immunotherapy with single-agent IL-2 (aldesleukin) can induce complete and 
durable responses in patients with metastatic melanoma and renal cell carcinoma.8 However, 
effective recombinant human IL-2 treatment requires doses that invariably generate 
substantial toxicity, necessitating inpatient administration and intensive supportive care, 
restricting its widespread use. Another IL-2 and IL-15Rβγ agonist, IL-15, is closely related 
to IL-2 and signals through the shared receptor IL-2 and IL-15Rβγ. Both cytokines promote 
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CD8-positive T-cell and natural killer (NK)-cell activation and proliferation. However, IL-2 
preferentially leads to expansion of regulatory T cells that express the unique IL-2Rα 
subunit, facilitating high-affinity IL-2 binding. Treatment with single-agent, recombinant-
human IL-15 (rhIL-15) was recently assessed in patients with metastatic melanoma and was 
shown to be safe, to act on IL-2Rβγ-positive lymphocytes such as CD8-positive T cells and 
NK cells, and to induce regression of lung metastases in two patients.9 Although rhIL-15 
treatment is promising, pre-associating IL-15 with its soluble receptor (IL-15Rα) can lead to 
a roughly 50-fold increase in biological activity.10–13
ALT-803 is a pharmacological grade IL-15/IL-15Rα complex fused to an IgG1 Fc, in which 
IL-15 is additionally mutated (asn72asp) to further increase biological activity and agonism 
of the IL-2 and 15βγ receptor.14 Although IL-2 and IL-15Rβγ agonists and PD-1 
monoclonal antibodies have shown clinical success as monotherapies in some patients, no 
published studies have assessed the administration of these two classes of agents 
concomitantly, although trials of similar concepts by other groups are ongoing 
(NCT02983045, NCT02964078, and NCT02452268). Preclinical studies have shown benefit 
of combining these two classes of drugs.15 In this trial, we assess the safety of the 
combination of ALT-803 and nivolumab immunotherapy, and the anti-tumour activity of 
cytokine treatment in the treatment of NSCLC.
Methods
Study design and participants
In this non-randomised, open-label, phase 1b trial, patients aged 18 years and older with 
histologically or cytologically confirmed stage IIIB or IV NSCLC (or recurrent disease 
following previous radiotherapy or surgical resection) were enrolled from three academic 
hospitals in the USA. Eligible patients had measurable disease as assessed by Response 
Evaluation Criteria In Solid Tumors (RECIST, version 1.1), an Eastern Cooperative 
Oncology Group performance status of 0 or 1, adequate organ function, were eligible to 
recieve anti-PD-1 immunotherapy, had no known autoimmune disease, and had progressed 
after previous treatment. Patients who had progressed after at least 3 months of single-agent 
previous PD-1 immunotherapy with nivolumab, pembrolizumab, or atezolizumab were 
eligible. Those who previously responded or had stable disease as best response to anti-PD-1 
immunotherapy before progression after a minimum duration of 3 months of treatment in the 
case of stable disease were defined as relapsed. Patients whose best response was 
progressive disease after a minimum duration of 3 months of single-agent PD-1 treatment 
were defined as refractory. Any previous treatment with other anti-PD-1, anti-PD-L1, anti-
PD-L2, anti-CD137, or anti-CTLA-4 antibodies was an exclusion criterion for 
immunotherapy naive patients. Prior anti-PD-1 therapy was allowed for the relapsed and 
refractory population. Other key exclusion criteria included anti-cancer treatment within 14 
days of registration; New York Heart Association Class III or IV heart failure and other 
cardiac morbidities; known autoimmune disease requiring active treatment; and CNS 
metastases, with the exception of patients who had asymptomatic CNS disease with 
metastases numbering five or fewer with no single lesion greater than 2 cm in diameter. 
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Patients with symptomatic CNS disease were required to have lesions treated previous to 
enrolment. A full list of the inclusion and exclusion criteria is in the appendix (pp 54–56).
The study was designed in compliance with the International Conference on Harmonization 
Good Clinical Practice and the FDA regulations for the conduct and monitoring of clinical 
investigations and sound research practice. The study protocol, consent procedures, and 
amendments were approved by the local institutional review board of each treating 
institution. Written informed consent was obtained from all participating patients in 
accordance with the principles described by federal regulatory guidelines. Study data were 
collected and managed using REDCap electronic data capture tools hosted at The Medical 
University of South Carolina (MUSC; Charleston, SC, USA).16
Procedures
Patients received weekly subcutaneous ALT-803 injection at four escalating dose levels: 6, 
10, 15, or 20 μg/kg on weeks 1–5 of four 6-week cycles in combination with intravenous 
nivolumab every 14 days. Treatment was administered by infusion nurses in the outpatient 
setting. Three patients were enrolled per ALT-803 dose level; an additional three patients 
received treatment in the 15 μg/kg cohort before proceeding to the highest dose level (the 20 
μg/kg cohort). The initial protocol did not include the highest dose level of 20 μg/kg, but 
because of the absence of dose-limiting toxicity through the ALT-803 dose of 15 μg/kg, the 
trial was amended to add the dose level of 20 μg/kg on April 11, 2017 (as approved by the 
MUSC institutional review board). A low dose of 3 μg/kg of ALT-803 was also included in 
the protocol as a possible dose level to be explored in the event of toxicities at higher doses, 
but no patients were treated at that dose level. All study treatments were administered in the 
outpatient setting.
During the trial, the approved intravenous dose of nivolumab administered every 2 weeks 
was changed from 3 mg/kg to a flat 240 mg dose after FDA-approved dosing changed, and 
the protocol treatment schema was amended to reflect this change on Sept 20, 2016 
(approved by the MUSC institutional review board). All patients given 20 μg/kg ALT-803 
were given the nivolumab flat dosing regimen. Patients enrolled prior to this amendment 
were switched to nivolumab flat dosing at 240 mg every 14 days intravenously.
Efficacy was monitored at the beginning of each 6-week cycle and compared to baseline 
measurements using interval imaging ordered in accordance with RECIST 1.1 and 
interpreted using immune-related RECIST (irRECIST; version 1.1). Radio logical 
assessments in this phase 1b study were not confirmed. PD-L1 status was established in all 
enrolled patients using a commercially available, Clinical Laboratory Improvement 
Amendments (CLIA)-certified assays employing either the 22C3 (Dako, Santa Clara, CA, 
USA) or SP142 (Ventana, Tucson, AZ, USA) antibodies. Patients could discontinue study 
treatment for any of the following criteria for removal from study: all dose-limiting toxic 
effects, radiographic disease progression, clinical disease progression, inter-current illness or 
study treatment-related toxic effect that would in the judgment of the investigator affect 
assessments of clinical status to a significant degree or require discontinuation of study 
treatment, patient preference, treatment delay greater than 6 weeks for any adverse event, 
concomitant treatment with a prohibited drug, or patient non-compliance.
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Safety was monitored in all patients with clinical and laboratory assessments during the 28-
day dose-limiting toxicity observation period and throughout treatment. The National 
Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) was used 
to grade adverse events. Patients continued to receive treatment until disease progression, 
unacceptable toxicity, or 24 months of treatment. Dose reductions were not permitted. 
Treatment delay for adverse events was allowed, with treatment allowed to restart if toxicity 
resolved to grade 0 or 1. Clinical and laboratory monitoring (haematological and chemistry) 
for safety was done with each dose administration.
For pharmacokinetic studies, analysis of serum ALT-803 was established before and after 
ALT-803 administration. At the time of the the initial dose of ALT-803, blood was collected 
at various timepoints (days 0, 4, 7, and 14), and serum samples were prepared. Serum 
concentrations of ALT-803 (pg/mL) were assessed by ELISA.
For immune correlate analysis, peripheral blood mononuclear cells and serum were obtained 
at the timepoints indicated (day 0, 6 h, 24 h, and days 4, 7, and 14). Briefly, peripheral blood 
mononuclear cells were stained for flow cytometric analysis and samples were acquired on a 
BD LSRFortessa (BD Biosciences, San Jose, CA, USA). Flow cytometric data were 
analysed using FlowJo software (Ashland, OR, USA). Serum was sent to Eve Technologies 
(Calgary, AB, Canada) for analysis using bead-based multiplexing technology. Genomic 
DNA was prepared from peripheral blood mononuclear cells and sent to Adaptive 
Biotechnologies (Seattle, WA, USA) for T-cell receptor (TCR) sequencing and analysis 
using the immunoSEQ Assay in view of the findings of previous studies showing an 
association between response to PD-1 blockade and changes in the TCR β-chain repertoire.
17,18
 Additional details of the procedure are included in the appendix (p 19).
Outcomes
The primary endpoint of the phase 1b study was the occurrence of dose-limiting toxicity 
(caused by both non-immune-related and immune-related adverse events) in order to define 
the safety and tolerability of escalating doses of ALT-803 used in combination with 
nivolumab and to establish a recommended phase 2 dose; the appendix provides a full 
definition of dose-limiting toxicity (appendix p 2). The secondary endpoints of the phase 1b 
study included duration of response, progression-free survival, overall survival, 
pharmacokinetics (ALT-803 Cmax and area under the curve), immunogenicity, plasma 
cytokine concentration, and lymphocyte subpopulation characterisation. In cases of 
pseudoprogression, this was defined as a more than 20% increase in tumour burden as 
measured by irRECIST 1.1 at timepoints up to 12 weeks previous to a partial or complete 
response. Progression-free survival and overall survival were measured from start of 
treatment to time of progression or death, respectively. Objective responses were defined as 
complete and partial responses as determined using RECIST (version 1.1). The proportion 
of patients achieving an objective response and disease control are post-hoc analyses for the 
phase 1b portion of the trial. All patients were included in analyses for primary and 
secondary endpoints per protocol. For the phase 1b part of the study, efficacy outcome 
stratified by PD-L1 status was not prespecified and is a post-hoc analysis.
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Statistical analysis
We postulated that the addition of ALT-803 to nivolumab would be safe and that the 
combination would be more effective than single-agent nivolumab alone. Dose escalation 
was done according to a continual reassessment method with the following stopping rules: 
the sample size reached 21 patients, the recommended dose for the next cohort had already 
been given to 12 patients, or the estimated dose-limiting toxicity at dose –1 (ie, the lowest 
planned dose of 3 μg/kg) was 40% or higher.19 Skipping of dose levels was not permitted 
and so in the absence of dose-limiting toxicity, doses were considered sequentially with 
three patients per dose level.
Patient characteristics and clinical outcomes are presented using simple descriptive statistics. 
The product-limit (ie, Kaplan-Meier) estimator was used to estimate median progression-
free survival and overall survival with corresponding 95% CIs. Progression-free survival 
data were censored for participants who were lost to follow-up but progression free at the 
time of study withdrawal, and for patients on study and progression free as of Nov 30, 2017. 
Overall survival data were censored for participants still alive as of Nov 30, 2017. Data 
analyses were done with R (version 3.2.3). The appendix provides the methods used for the 
description of correlative science statistics.
The study is registered with ClinicalTrials.gov, number NCT02523469; phase 2 enrolment 
of patients is ongoing.
Role of the funding source
Altor Bioscience supplied ALT-803 and performed pharmacokinetic and immunogenicity 
assays of the study drugs, and provided input into the study design and interpretation of data, 
and in the writing, review, and approval of the manuscript. The other funders had no role in 
the study. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Jan 18, 2016, and June 28, 2017, 23 patients were enrolled and 21 were treated and 
assessed for safety (table 1, appendix p 3). Two patients did not receive any treatment 
because of the development of inter-current illness during enrolment, one patient due to 
leucopenia and one patient due to pulmonary dysfunction. Of the 21 patients, three patients 
were enrolled in the 6 μg/kg ALT-803 dose cohort, three in the 10 μg/kg cohort, six in the 15 
μg/kg cohort, and nine in the 20 μg/kg cohort. No patients with untreated CNS metastases 
were enrolled in the study. Trial enrolment was stopped on July 27, 2017, due to the trial 
meeting its primary endpoint of defining a recommended phase 2 dose.
Median duration of follow-up in all patients was 6·9 months (IQR 5·5–12·0 months). Safety 
and tolerability were assessed in the 21 patients who received at least one dose of ALT-803. 
Frequency and severity of adverse events did not increase with higher doses of ALT-803 and 
a maximum tolerated dose was not reached (appendix p 5). No dose-limiting toxicities were 
recorded. The most frequent adverse events were grade 1 or 2 and consisted of injection-site 
reactions, fever, fatigue, chills, nausea, pain, and flu-like symptoms (table 2, appendix p 5). 
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Hypotension, when present, was mild, with no events worse than grade 2, and did not 
require inpatient care. Grade 3 lymphocytopenia occurred in two participants; both events 
resolved spontaneously and did not recur with continued treatment. ALT-803 did not 
increase the risk of immune-mediated adverse events associated with nivolumab, with only 
one episode of grade 2 pneumonitis observed on trial that resolved without steroid treatment. 
No grade 4 or 5 adverse events were recorded. A patient who experienced myocardial 
infarction was discontinued from the 15 μg/kg cohort; (judged to be possibly treatment 
related), and no other patients were discontinued from treatment for adverse events. All 
treatment-related adverse events were managed on an outpatient basis, with the exception of 
an admission for pain control in one patient who had extreme pseudoprogression previous to 
response. Pseudoprogression in this patient resulted in a nearly initial 300% increase in 
tumour volume (according to irRECIST 1.1) and a subsequent 84% decrease in tumour 
volume from baseline and ongoing treatment for more than 17 months. The recommended 
phase 2 dose of ALT-803 was established as 20 μg/kg subcutaneously once per week in 
combination with 240 mg intravenous nivolumab every 2 weeks.
ALT-803 concentrations were established to define the pharmacokinetics after subcutaneous 
dosing (figure 1). Serum concentrations of ALT-803 reached near-peak concentrations 
between 2 and 6 h post-injection for all dose levels studied. Patients who received doses of 
10 μg/kg and higher had a modest upward trend in peak concentrations (Cmax) after 6 h, 
which continued until at least 24 h post-injection. Dose cohorts of 10 μg/kg and higher had 
similar Cmax concentrations 24 h after treatment (figure 1).
Seven (33%) of the 21 patients in the study developed detectable anti-ALT-803 antibody 
titres in sera after multidose treatment (two patients in the 10 μg/kg cohort, three patients in 
the 15 μg/kg cohort, and two patients in the 20 μg/kg cohort; appendix p 6). No anti-
ALT-803 antibodies were detected in the 6 μg/kg cohort (n=3). In five of the seven patients 
with detectable anti-ALT-803 antibodies, these were initially recorded following 
administration of four doses of ALT-803. Titres in four of the seven positive patients were 
only detectable in one of the seven timepoints studied over the four 6-week treatment cycles. 
The highest titre recorded in the study was 315, which decreased to 153 or lower at 
subsequent timepoints. Three of seven patients had detectable titres at more than one 
timepoint. No anti-nivolumab antibodies were detected in any of the patients enrolled in this 
study. Of the seven patients who developed detectable anti-ALT-803 antibodies, three (42%) 
responded to treatment (all partial responses). No additional adverse events and no 
impairment in NK-cell counts based on the assessment of peripheral blood mononuclear cell 
samples were noted in these seven patients.
In the post-hoc analysis, six (29%) of 21 patients achieved an objective response (figure 2, 
table 3). All responses were partial responses, with no complete responses recorded. Nine 
(43%) of 21 patients experienced a decrease in the size of their target lesions, and 16 (76%) 
of 21 patients achieved disease control (stable disease, partial response, and complete 
response). Duration of response data will be reported separately. Progressive disease was 
recorded in ten patients and eight patients died. Median progression-free survival was 9·4 
months (95% CI 3·0–not recorded), and median overall survival was 17·4 months (95% CI 
9·0–not recorded), with six patients receiving ongoing treatment (figure 2B). Responses 
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were recorded in patients with various different types of mutation status (appendix p 6). No 
dose-dependent response was noted (appendix p 7).
In a post-hoc exploratory analysis of response according to PD-L1 expression status, of four 
patients PD-L1 expression higher than 50% (classified as PD-L1-positive), three had 
objective responses and a fourth has stable disease with ongoing treatment at 6 months 
(figure 2). Both patients with PD-L1 expression between 1% and 50% have had stable 
disease at 6 and 17 months with ongoing treatment, the latter harbouring an EGFR exon 20 
insertion and who has had a 27% reduction in the size of their target lesions (figure 2). In ten 
patients with PD-L1 expression lower than 1% (classified as PD-L1-negative), seven (70%) 
achieved stable disease or better, with three (30%) partial responses (table 3, appendix p 8).
11 patients enrolled to the trial had previously received a single-agent PD-1 monoclonal 
antibody and progressed after at least 3 months of treatment (figure 2B). The proportion of 
PD-1 treatment-resistant patients who achieved disease control was 91% (ten of 11 patients), 
with three (27%) partial responses and seven (64%) patients with stable disease (figure 2B, 
table 3). Two objective responses occurred when ALT-803 was added to uninterrupted 
nivolumab at the time of relapse on single-agent anti-PD-1 immunotherapy, showing 
evidence of anti-tumour activity for ALT-803 in NSCLC. Furthermore, we noted a partial 
response to study treatment in a relapsed patient whose best response to 9·5 months of 
previous nivolumab therapy was stable disease. Stable disease was also achieved in another 
patient who was refractory to previous single-agent anti-PD-1 immunotherapy.
The clinical experience of one patient who had not received previous immunotherapy is 
noteworthy. This patient achieved an initial partial response (65% decrease in target lesion 
size) to study treatment in the 6 μg/kg ALT-803 dose cohort but then progressed after about 
10 months on treatment. The patient then enrolled in a trial of docetaxel plus trametinib for 
patients whose tumours possess a KRAS mutation. Upon no response to this treatment, the 
patient was retreated with nivolumab and ALT-803 at 15 μg/kg using a single-patient 
investigational new drug application and the patient experienced a second, significant 
response (100% target lesion size decrease by RECIST 1.1, but this was only classed as a 
partial response due to the persistence of a non-target lesion, appendix p 9). This patient’s 
second experience with ALT-803 plus nivolumab was not included in any outcome measures 
of the trial.
Combination treatment-induced changes in the periphery were most evident in NK cells and 
to a lesser degree in CD8-positive T cells (as assessed in all 21 treated patients; figure 3A, 
appendix p 10). Within 7 days of initiation of study treatment, NK-cell frequency on average 
more than doubled at all dose levels of ALT-803 (figure 3A). The preferential expansion of 
NK cells over CD8-positive T cells has been previously reported with single agent 
recombinant IL-15,9 and could be a consequence of higher surface expression of the shared 
IL-2 and 15Rβγ (CD122 and CD132) on NK cells than CD8-positive T cells (appendix p 
11). Although CD8-positive T-cell frequencies did not increase to the same extent as NK 
cells, some patients showed a notable increase in biological activity of CD8-positive T cells 
at cycle 1, day 4, based on Ki67 staining (figure 3B, C, appendix p 12). Importantly, we 
noted changes in NK cells and CD8-positive T cells after ALT-803 was added to continuous 
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nivolumab treatment in two patients (Figure 3B, appendix p 10), showing that these 
biological effects were ALT-803 dependent (rather than being caused by nivolumab). 
Finally, as expected, we recorded minimal expansion of the regulatory T-cell population and 
an increase in the CD8-positive T cell to T regulatory cell ratio (appendix pp 10, 12, 13). In 
some patients, study treatment resulted in raised concentrations of inflammatory cytokines, 
notably interferon γ (IFNγ) and IL-6, which is indicative of the ability of IL-15-based 
treatments to induce systemic immune activation. Serum concentrations of these cytokines 
were highest 4–7 days after initiation of treatment (figure 3D). Induction of IFNγ as 
measured by fold change was notable in patients with PD-L1-negative tumours (those with 
<1% PD-L1 expression; appendix p 14). Consistent with an induction of systemic immune 
activation, study treatment was also associated with day 4 upregulation of HLA-DR 
expression on circulating CD11c-positive cells (figure 3E, appendix p 15). Finally, for 
comparison with other correlates, the appendix provides values from complete blood counts 
(appendix p 16).
In a comparison of measurements over the course of the first cycle performed on day 4, 7, 
and 14 after the start of treatment, the highest biological responses were on day 4 as 
reflected by both the increase in the staining intensity of Ki67 in NK cells (data not shown) 
and by increased concentration of circulating IFNγ (figure 3D), consistent with transient 
induction of immune responses between weekly ALT-803 administration. In the second 
cycle of treatment, peak day 4 responses were notably reduced in comparison to the first 
cycle (appendix p 17), suggesting that prolonged continuous treatment might lead to reduced 
biological responsiveness to subsequent treatment.
In an exploratory post-hoc analysis, we assessed differences in induced immune parameters 
related to patients’ best clinical response (figure 3F). In an initial subgroup analysis (n=7), 
participants responding to trial treatment showed reduced TCR clonality at baseline, as 
might be expected in patients treated with single-agent anti-PD-1 immuotherapy (figure 3F). 
Notably, one patient who initially showed pseudoprogression, which roughly tripled their 
tumour volume before they eventually achieved a notable response, showed the broadest 
baseline peripheral TCR repertoire and also the most dynamic change in the T-cell receptor 
repertoire following treatment (figure 3F, G). Multi-spectral imaging of pre-treatment 
tumour biopsy samples shows the relation between CD8-positive T cells and PD-L1-positive 
tumour and immune cells, and ongoing efforts will correlate multiple parameters of the 
tumour microenvironment with treatment response (appendix p 18).
Discussion
In this study we show that ALT-803 is safe, tolerable, and can be conveniently administered 
in combination with an anti-PD-1 checkpoint antibody for patients with NSCLC in an 
outpatient setting. The clinical experience of administering ALT-803 as part of this regimen 
is in stark contrast to that of IL-2, which requires supervision in the intensive-care setting 
due to its severe toxicity when given at its approved dose. More importantly, ALT-803 did 
not increase the severity of or induce additional adverse events associated with nivolumab 
immunotherapy, except for low-grade and transient constitutional adverse events such as 
fever and injection-site skin rash at a dose level as high as 20 μg/kg with weekly dosing. At 
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this dose level, the activation of the immune system is evident based on NK and T-cell 
proliferation and induction of serum cytokine levels. Based on the combination of safety and 
potent biological activity, the 20 μg/kg weekly dosing was selected to move forward with the 
phase 2 portion of the trial. However, immune therapeutics can often be effective at a wide 
range of dose levels, and therefore future studies might be required to identify the optimal 
dosing of this agent with anti-PD-1 monoclonal antibodies treatment.
Notably, adverse events recorded in patients treated with ALT-803 and nivolumab in our 
study contrast markedly with published data about patients treated with ipilimumab (anti-
CTLA-4 monoclonal antibodies) and nivolumab, the only FDA-approved dual checkpoint 
inhibitor treatment. Whereas ipilimumab and nivolumab treatment-related adverse events 
have led to treatment discontinuation in up to 39% of patients treated with the only approved 
regimen5 (although treatment discontinuations due to the toxicity of regimens modified for 
the NSCLC population seem to be less at 10–13%),20 toxicity due to ALT-803 plus 
nivolumab led to only one treatment discontinuation in our study. With regard to immune-
mediated adverse events, we observed one case of grade 2 pneumonitis in our trial, which 
resolved without steroids, and no other immune-mediated adverse events associated with 
nivolumab exposure. Furthermore, there were no dose-limiting or grade 4 or 5 adverse 
events recorded with ALT-803 and nivolumab combination treatment. The fact that ALT-803 
did not increase adverse events associated with nivolumab is consistent with patients who 
received combination treatment of ALT-803 with another immunotherapy (BCG) for non-
muscle-invasive bladder cancer, such that the addition of ALT-803 did not exacerbate 
adverse events typically associated with BCG treatment.21
Furthermore, we report that ALT-803 can re-induce objective responses to anti-PD-1 
immunotherapy after treatment relapse or failure. It has been reported that about 8% of 
patients with NSCLC treated past progression had partial responses with continued PD-1 
monoclonal antibodies treatment.22 Although it is possible that this phenomenon might 
explain objective responses to ALT-803-nivolumab combination treatment after PD-1 
treatment failure, the re-induction of response coincided directly with initiation of ALT-803 
after progression in patients with relapsed disease treated with uninterrupted nivolumab. 
Moreover, disease control was asserted in all ten patients who had relapsed disease after 
previous anti-PD-1 immunotherapy. The ability of ALT-803 to safely re-induce objective 
responses to immunotherapy in patients whose disease has relapsed after previous single-
agent PD-1 monoclonal antibodies treatment has important implications in solid tumour 
oncology beyond NSCLC. Taken together with compelling progression-free survival and 
overall survival data, the study results suggest that ALT-803 represents a novel immuno 
therapeutic agent that could augment the anti-tumour activity of checkpoint inhibitors in 
several treatment settings.
In second-line treatment for NSCLC, roughly 20% of patients achieve an objective response 
to anti-PD-1 treatment, but in patients with non-squamous NSCLC who have PD-L1 
negative (<1%) tumours, only about 9% of patients achieve a clinical response.1 In our study 
with 19 (90%) of 21 patients with non-squamous NSCLC, the combination of ALT-803 and 
nivolumab induced clinical responses in 30% of PD-L1-negative patients and yielded disease 
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control in 70%. In patients whose tumours lack PD-L1 expression, ALT-803 could therefore 
have substantial application in broadening the reach of benefit from checkpoint inhibitors.
Broadly, our results suggest that administration of an IL-2Rβγ agonist might be useful in 
overcoming resistance to anti-PD-1 monoclonal antibody treatment. Mechanistically, there 
are several possibilities that could facilitate improved response rates. Systemic induction of 
inflammatory cytokines such as IFNγ, could facilitate the conversion of an immunological 
cold tumour into a hot tumour. This theory could directly explain why patients with PD-L1-
negative tumours might have an improved response rate with the addition of ALT-803 to 
their anti-PD-1 treatment. Another possibility is that ALT-803 drives expansion of 
neoantigen-reactive T cells, which is supported by our TCR sequencing data; however, this 
post-hoc subgroup analysis was small, and additional patient data will be needed for more 
conclusive assessment of these parameters. The low TCR clonality in the peripheral blood at 
baseline that we recorded is consistent with published reports with single-agent anti-PD-1 
immunotherapy. This ability of ALT-803 to drive potent expansion of NK cells could have 
particular value because MHC class I is lost on a substantial proportion of NSLCL tumours,
23
 thereby making these tumours potentially susceptible to NK-cell-mediated killing. These 
questions are being addressed in our ongoing phase 2 study.
Although anti-ALT-803 antibodies were detected in seven study patients, there was no 
apparent association with toxic effects and no decrease in anti-tumour activity (as indicated 
by the fact that three of these seven patients had a partial response). Further study in 
additional patients is required to understand the biological effect of these antibodies. It is 
relevant that anti-drug antibodies have been reported in many trials using recombinant 
proteins and antibodies.24 In one study, anti-IL-2 antibodies were detected in roughly half of 
patients, and development of these antibodies was not associated with a decrease in the 
treatment effect.25
A crucial question for future studies is to determine the optimal timing and duration of 
adding an IL-2Rβγ agonist to anti-PD-1 treatment. Our immune correlative work provides 
some insights in this area. Consistent with previous reports with the administration of single-
agent rhIL-15 in human patients,9 we detected induction of Ki67 in CD8-positive T and NK 
cells and serum cytokines such as IFNγ and IL-6 at early timepoints after ALT-803 and 
nivolumab administration. These changes observed in immune correlates correspond with 
fevers and flu-like symptoms, and were clearly related to ALT-803 because they were not 
recorded in patients receiving single-agent nivolumab. However, although inflammatory 
side-effects, including ALT-803 injection-site reactions, were recorded during the first cycle 
of treatment, by the second cycle of treatment these symptoms were greatly diminished. 
Notably, the reduction in inflammatory side-effects showed a strong correlation with 
reduced induction of Ki67 and IFNγ. Evidence of tolerance to sustained cytokine treatment 
has been previously described for IL-2 and IL-15.26–29 For comparison, it may be relevant 
that the FDA-approved dose of IL-2 is given in high-dose pulses that typically yield ongoing
—even worsening—symptoms with subsequent treatment cycles. Thus, a crucial goal for 
future research could be to determine not only optimal dosing but also whether treatment 
breaks are important. Further studies are being planned to investigate the optimal dose and 
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schedule of ALT-803 in combination with anti-PD-1 treatment, both preclinically and 
clinically (NCT03228667).
Pseudoprogression in two patients on combination treatment with ALT-803 and nivolumab 
was recorded in this study. One patient experienced an extreme variant of pseudoprogression 
with tripling in the size of his tumours, causing severe pain, before he subsequently achieved 
a response to treatment. The potential for pseudoprogression must be considered in the 
clinical care of patients receiving this combination immunotherapy. The response assessment 
process might need adjustment to reflect this phenomenon and consideration must be given 
before treatment is stopped early in such patients. Our data indicate that ALT-803 and anti-
PD-1 immunotherapy should be continued until confirmation of progression on subsequent 
imaging and careful assessment so as not to forgo an opportunity to experience benefit from 
combination treatment. The degree of pseudoprogression might, in fact, be a marker of 
quality of eventual response.30
Although our study is limited by the small number of treated patients, enrolment efforts are 
ongoing to accumulate experience with this treatment combination in a study population that 
more broadly mirrors the population of patients with NSCLC in the phase 2 portion of the 
clinical trial that stratifies patient based on PD-L1 status, prior exposure to anti-PD-1 
immunotherapies, and EGFR mutation status. For example, there were fewer than expected 
current or former smokers and a high proportion of patients with PD-L1-negative tumours in 
our patient population. Additionally, this phase 1b study with a safety-related primary 
endpoint was not designed to directly assess the efficacy of ALT-803 and nivolumab 
compared with either single-agent nivolumab or second-line single-agent chemotherapy. 
Although we have determined a safe and tolerable dose for the ongoing phase 2 trial 
(NCT02523469), questions regarding the duration and timing of treatment, and dose-
response association remain unanswered. Further accrual for the phase 2 trial will also allow 
us to achieve greater precision in the estimation of benefit for several subgroups based on 
genetic and tumour microenvironment characteristics. Moreover, since our correlate data 
show diminished effects at 6 weeks of treatment, de-intensification of administration of 
lymphocyte growth factor could potentially yield prolonged anti-tumour activity.
Overall, our findings from this phase 1b study show that ALT-803 can be safely 
administered with nivolumab entirely on an outpatient basis. To our knowledge, we provide 
the first findings for activity of an IL-15 treatment in patients with NSCLC. Perhaps of 
greatest importance, the ability of ALT-803, or an agonist targeting the shared IL-2 and 
IL-15Rβγ pathway, to re-induce responses in patients experiencing treatment failure with 
PD-1 treatments could have implications in a wide range of cancers.
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Research in context
Evidence before this study
Although there is recent scientific literature documenting the efficacy of single-agent 
PD-1 or PD-L1-blocking agents in cancer in human beings, including with non-small-cell 
lung cancer (NSCLC), most patients with NSCLC do not respond to single-agent anti-
PD-1 immunotherapy, and nearly all responders eventually progress. In contrast to agents 
that block immune checkpoints, interleukin-2 (IL-2) and IL-15-based cytokine treatments 
target the IL-2Rβγ pathway, thereby augmenting lymphocyte responses. For more than 
20 years, IL-2 treatment has shown efficacy in metastatic melanoma and renal cell 
carcinoma, but there have been only anecdotal reports of efficacy in other cancers 
including NSCLC. Newer IL-2 and IL-15Rβγ targeting agents in development include 
NIZ985 (hetIL-15, IL-15 and IL-15Rα) and ALKS 4230 (IL-2 and IL-2Rα). We 
searched PubMed through Nov 17, 2017, for studies combining IL-2 or IL-15Rβγ 
agonists with PD-1-blocking or PD-L1-blocking agents using the following search terms: 
“IL-2 OR IL-15” and “nivolumab OR pembrolizumab OR atezolizumab OR avelumab 
OR durvalumab OR pidilizumab OR PD-1 OR PD-L1”. We also searched abstracts from 
the 2015, 2016, and 2017 American Society of Clinical Oncology (ASCO) annual 
meeting. Abstracts reported at ASCO 2017 included ongoing clinical studies combining a 
pegylated IL-2 molecule (NKTR-214) with PD-1 or PD-L1-blocking antibodies 
(NCT02983045). Although findings of preclinical studies show combining IL-2 and 
IL-15Rβγ agonists with anti-PD-1 monoclonal antibodies can improve anti-tumour 
responses, we found no published clinical studies assessing either the safety or efficacy of 
this combination in human patients.
Added value of this study
No dual immunotherapies or non-PD-1-directed targeted immunotherapeutics are 
approved for use in NSCLC; therefore, improved immunotherapeutic strategies to extend 
the therapeutic benefit to a larger proportion of patients with NSCLC and to resurrect 
clinical benefit when resistance to treatment occurs is a huge unmet need. This study is 
the first clinical report to assess safety or to report the efficacy of ALT-803 or any other 
IL-2 or IL-15Rβγ agonist cytokine administered in combination with anti-PD-1 
immunotherapy. The current study shows a potential role for a new class of therapeutic 
agent for the treatment of NSCLC.
Implications of all the available evidence
Our findings show that cytokine treatment with an IL-2 and IL-15Rβγ superagonist at 
doses capable of inducing anti-tumour immune responses is safe and feasible in the 
outpatient setting and that the cytokine complex might safely be combined with anti-
PD-1 immunotherapy. The ability of ALT-803 to re-induce immunotherapeutic response 
in PD-1-relapsed and refractory NSCLC should stimulate a surge of renewed interest in 
cytokine combination treatments for cancer.
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Figure 1: 
Pharmacokinetics of ALT-803 after subcutaneous administration
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Figure 2: Post-hoc clinical activity of ALT-803 in combination with nivolumab
(A) Best observed response for 21 patients given ALT-803 in combination with the US Food 
and Drug Administration (FDA)-approved dose of nivolumab (3 mg/kg then 240 mg flat 
dose after change in FDA approval). Upward arrows indicate the patient had a 180% 
increase in size of tumour by RECIST and is out of scale for the figure. (B) Best response by 
patient versus duration of treatment on study. Upper red line is more than 20% over baseline 
tumour burden; lower red line is less than 30% from baseline tumour burden, both measured 
by RECIST criteria. RECIST=Response Evaluation Criteria In Solid Tumors. *Progression 
due to a new lesion. †Target lesion decrease of 27%, but met RECIST 1.1 criteria for partial 
response.
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Figure 3: Immune correlates of patients given ALT-803 in combination with nivolumab
(A) The change in peripheral blood numbers of NK cells (CD56bright/dimCD16+CD3–), 
CD8-positive T cells (CD8+CD3+), and CD4-positive T cells (CD4+CD3+) in relation to 
pre-treatment assessment (appendix p 10 provides additional details). (B) Ki67 induction in 
immune cell subsets, measured in patient number 7 after the addition of ALT-803 treatment 
to ongoing nivolumab treatment. (C) Change in Ki67 concentrations (MFI) in lymphocyte 
subsets at day 4 versus pretreatment. Each symbol indicates one patient and colours indicate 
best response as depicted in the figure legend. Changes for NK cells and CD8-positive T 
cells differed significantly from 1, and all pairwise comparisons were statistically 
significant. (D) Serum interferon γ and interleukin-6 concentrations were measured 
longitudinally and the fold change was established in relation to pre-treatment assessment. 
Each line represents one patient. (E) Upregulation of HLA-DR on CD11c-positive cells was 
assessed by determining the fold change in percentage of HLA-DR-positive cells at day 4 
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versus pretreatment. Each symbol indicates one patient and the colours indicate best 
response. Fold changes differed significantly from 1. (F) T-cell receptor (TCR) 
immunosequencing of pretreatment peripheral blood mononuclear cells of the first seven 
trial patients. (G) Longitudinal analysis of TCR repertoire of first seven trial patients 
graphed as Morisita index. NK=natural killer. MFI=mean flouresence intensity. C=cycle. 
W=week. D=day. *p<0·01. **p<0·001. ***p<0·0001.
Wrangle et al. Page 21
Lancet Oncol. Author manuscript; available in PMC 2018 August 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wrangle et al. Page 22
Table 1:
Baseline characteristics
Patients (n=21)
Age (years) 55(46–67)
Sex
 Men 15 (71%)
 Women 6 (29%)
Ethnic origin
 White 18 (86%)
 Black 2 (10%)
 Asian 1 (5%)
Smoking status
 Never 9 (42%)
 Former 12 (57%)
Histology
 Squamous 2 (10%)
 Non-squamous 19 (90%)
ECOG performance status at baseline
 0 10 (48%)
 1 11 (52%)
PD-L1 expression
 0–<l% 10 (48%)
 ≥1–<50% 2 (10%)
 >50% 4 (20%)
 Unknown* 5 (24%)
Number of previous treatments regimens 1–9 (2)
 1 10 (48%)
 2–3 8 (38%)
 >3 3 (14%)
Previous platinum-based chemotherapy 21 (100%)
Previous definitive chemoradiation 4 (20%)
Prior PD-1 monoclonal antibody immunotherapy 11 (52%)
Mutations
 KRAS 6 (29%)
 EGFR 2 (10%)
 ALK rearranged 0 (0%)
 RET rearranged 1 (5%)
 ROS1 rearranged 0 (0%)
 BRAF 2 (10%)
Data are median (IQR), n (%), or range (average). ECOG=Eastern Cooperative Oncology Group.
*
Tumour not available for testing.
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Table 2:
Adverse events
All treated patients (n=21)
Grade 1–2 Grade 3
Constitutional
Injection-site reaction 19 (90%) 0
Flu-like symptoms 15 (71%) 0
Fever 11 (67%) 1 (5%)
Fatigue 10 (47%) 2 (10%)
Anorexia 4 (19%) 0
Chills 6 (29%) 0
Dizziness 5 (24%) 1 (5%)
Generalised muscle weakness 2 (10%) 0
Gastrointestinal
Nausea 8 (38%) 0
Constipation 4 (19%) 0
Vomiting 3 (14%) 0
Diarrhoea 2 (10%) 0
Dry mouth 2 (10%) 0
Mouth sore 2 (10%) 0
Respiratory
Cough 4 (19%) 0
Dyspnoea 4 (19%) 0
Cardiovascular
Hypotension 4 (19%) 0
Laboratory
Lymphocytopenia 0 2 (10%)
Increased alkaline phosphatase 0 1 (5%)
Anaemia 0 1 (5%)
Increased aspartate transaminase 0 1 (5%)
Pain or other
Pain 7 (33%) 0
Rash (not otherwise specified) 2 (10%) 0
Headache 2 (10%) 0
Back pain 1 (5%) 1 (5%)
Depression 1 (5%) 1 (5%)
Abdominal pain 0 1 (5%)
Myocardial infarction 0 1 (5%)
Data are n (%).
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Table 3:
Post-hoc objective responses and disease control
Objective responses (n, %, 95% CI) Disease control (n, %, 95% CI)
All patients 6 (29%, 11–52) 16 (76%, 53–92)
PD-1 relapsed and refractory 3 (27%, 6–61) 10 (91%, 59–99)
PD-LI negative (<1%) 3 (30%, 7–65) 7 (70%, 35–93)
PD-L1 positive (>50%) 3 (75%, 19–99) 4 (100%, 40–100)
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